Hormonal
Tirzepatide (5-15 mg once weekly) produces superior weight loss (16.5% to 22.4%) and glycemic control compared to GLP-1 monotherapies (liraglutide, semaglutide) and other glucose-lowering medications in patients with type 2 diabetes and obesity.
For adults with obesity or type 2 diabetes, tirzepatide (5-15 mg weekly) is a highly effective treatment that significantly reduces body weight (up to ~21%) and improves cardiovascular risk factors more than GLP-1 monotherapies like semaglutide or liraglutide. It requires weekly injections and lifestyle changes, with side effects like nausea being common but usually mild and temporary during dose increases.
Tirzepatide provided better efficacy than placebo and other commonly used glucose-lowering medications, such as semaglutide 1 mg, dulaglutide, insulin degludec, and glargine... In people without diabetes, tirzepatide 5 to 15 mg once weekly for the treatment of obesity (SURMOUNT-1) resulted in substantial reductions in body weight (16.5% to 22.4%) over 72 weeks.
Why this rating
Based on a systematic review of 23 studies, including RCTs, though some had high risk of bias.
Source
Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review
Helena Ramalho Arvate · International Journal of Nutrology · 2025
DOI 10.54448/ijn25102
More from this paper
- Liraglutide (3.0 mg once daily) combined with lifestyle changes is an effective treatment for obesity in patients with and without type 2 diabetes, resulting in significant weight loss and maintenance.Good
- Semaglutide (≥0.2 mg once weekly) demonstrates statistically significant weight loss compared to liraglutide 3.0 mg in patients with obesity without diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →